Civista Medical Center INC

Civista Medical Center INC was paid $2.01M by Medicaid between Jan 2018 and Nov 2024, across 64 billing codes. Its largest line is 99284, emergency room visit (serious) — 45% of everything it billed.

Box 24A · Dates of service

Paid by month

Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider

By year, as a table

Year	Claims	Paid
2018	15,195	$215K
2019	12,163	$259K
2020	9,121	$268K
2021	13,815	$360K
2022	12,571	$353K
2023	9,605	$348K
2024incomplete	6,126	$208K

Box 24 · Service lines

What it billed for

Code	Service	Share	Claims	Bene. records	Paid
99284	Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity	45%	6,983	5,959	$912K
99283	Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity	23%	4,655	4,027	$458K
99285	Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life	13%	1,405	1,274	$256K
99281	Emergency department visit for the evaluation and management, self-limited or minor	6.2%	3,552	2,938	$125K
G0378	Hospital observation service, per hour	3.2%	260	175	$65K
80053	Comprehensive metabolic panel	2.1%	8,287	6,750	$41K
85025	Blood count; complete (CBC), automated, and automated differential WBC count	1.2%	8,838	6,993	$25K
93010	Electrocardiogram, routine ECG with at least 12 leads; interpretation and report only	1.1%	7,920	5,871	$23K
71045	Radiologic examination, chest; single view	<1%	4,006	3,478	$19K
G0463	Hospital outpatient clinic visit for assessment and management of a patient	<1%	962	525	$18K
81001		<1%	2,723	2,445	$10K
70450	Computed tomography, head or brain; without contrast material	<1%	1,695	1,524	$9K

52 more codes

87636	Infectious agent detection by nucleic acid; SARS-CoV-2 and influenza virus types A and B	<1%	228	$7K
84484		<1%	3,389	$6K
71046	Radiologic examination, chest; 2 views	<1%	391	$6K
74177	Computed tomography, abdomen and pelvis; with contrast material	<1%	356	$5K
99282	Emergency department visit for the evaluation and management, low to moderate severity	<1%	105	$4K
83690		<1%	2,469	$3K
84703		<1%	782	$2K
J0131	Injection, acetaminophen, not otherwise specified,10 mg	<1%	101	$2K
87804	Infectious agent antigen detection by immunoassay; Influenza, each type	<1%	75	$2K
94640	Pressurized or nonpressurized inhalation treatment for acute airway obstruction	<1%	97	$2K
80307	Drug test(s), presumptive, any number of drug classes; immunoassay	<1%	96	$2K
82553		<1%	540	$1K
J7030	Infusion, normal saline solution , 1000 cc	<1%	2,571	$1K
83735		<1%	3,070	$1K
83880		<1%	765	$1K
82550		<1%	1,936	$1K
87086	Culture, bacterial; quantitative colony count, urine	<1%	505	$783.96
93971		<1%	25	$706.96
85610		<1%	1,700	$531.41
80048	Basic metabolic panel (calcium, ionized)	<1%	501	$415.13
74176	Computed tomography, abdomen and pelvis; without contrast material	<1%	51	$394.19
J2270	Injection, morphine sulfate, up to 10 mg	<1%	719	$379.95
87088		<1%	190	$345.83
87077		<1%	84	$339.16
81003		<1%	569	$295.14
85027		<1%	124	$291.50
85730		<1%	1,053	$260.25
G0480	Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed	<1%	94	$164.86
J2405	Injection, ondansetron hydrochloride, per 1 mg	<1%	2,000	$144.23
J0696	Injection, ceftriaxone sodium, per 250 mg	<1%	32	$104.70
87040		<1%	41	$89.61
83605		<1%	251	$66.59
U0004	2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc, making use of high throughput technologies as described by cms-2020-01-r	<1%	509	$64.95
85379		<1%	69	$58.80
J1885	Injection, ketorolac tromethamine, per 15 mg	<1%	158	$45.62
94760		<1%	14	$36.28
J3010	Injection, fentanyl citrate, 0.1 mg	<1%	363	$27.79
93005	Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report	<1%	15	$24.03
0241U	Neonatal screening for hereditary disorders, genomic sequence analysis panel	<1%	29	$22.41
J2704	Injection, propofol, 10 mg	<1%	249	$10.57
J1100	Injection, dexamethasone sodium phosphate, 1 mg	<1%	81	$2.45
J1170	Injection, hydromorphone, up to 4 mg	0%	45	$0.00
J7050	Infusion, normal saline solution, 250 cc	0%	607	$0.00
J0690	Injection, cefazolin sodium, 500 mg	0%	29	$0.00
J2001	Injection, lidocaine hcl for intravenous infusion, 10 mg	0%	25	$0.00
U0002	2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc	0%	14	$0.00
71275	Computed tomographic angiography, chest, with contrast material	0%	15	$0.00
0270		0%	26	$0.00
J2272	Injection, morphine sulfate (fresenius kabi), not therapeutically equivalent to j2270, up to 10 mg	0%	40	$0.00
J7120	Ringers lactate infusion, up to 1000 cc	0%	62	$0.00
87186		0%	28	$0.00
G1004	Clinical decision support mechanism national decision support company, as defined by the medicare appropriate use criteria program	0%	22	$0.00

Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.

From NPPES

Who's on the registration

Authorized officialZANGER, ALBERT (CHIEF FINANCIAL OFFICER)